Head to Head Contrast: Pathfinder Cell Therapy (OTCMKTS:PFND) & Nuvation Bio (NYSE:NUVB)

Nuvation Bio (NYSE:NUVB) and Pathfinder Cell Therapy (OTCMKTS:PFND) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.

Earnings & Valuation

This table compares Nuvation Bio and Pathfinder Cell Therapy”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90 million	35.32	-$204.63 million	($0.44)	-14.50
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A

Pathfinder Cell Therapy has lower revenue, but higher earnings than Nuvation Bio.

Analyst Ratings

This is a breakdown of recent ratings for Nuvation Bio and Pathfinder Cell Therapy, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1	2	8	0	2.64
Pathfinder Cell Therapy	0	0	0	0	0.00

Nuvation Bio presently has a consensus price target of $13.00, suggesting a potential upside of 103.73%. Given Nuvation Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Nuvation Bio is more favorable than Pathfinder Cell Therapy.

Institutional & Insider Ownership

61.7% of Nuvation Bio shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 15.1% of Pathfinder Cell Therapy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Nuvation Bio and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Pathfinder Cell Therapy	N/A	N/A	N/A

Summary

Nuvation Bio beats Pathfinder Cell Therapy on 6 of the 9 factors compared between the two stocks.

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.